Lunan Best

Lunan Pharmaceutical Group is a comprehensive pharmaceutical group integrating the production, research, and sales of traditional Chinese medicine, chemical drugs, and biological products. It is a national innovative enterprise and a key national high-tech enterprise. Its member enterprises include Lunan Hope Pharmaceutical Co., Ltd., Lunan Best Pharmaceutical Co., Ltd., Shandong New Era Pharmaceutical Co., Ltd., and Lunan New Era Pharmaceutical Co., Ltd. It ranks among the top 500 competitive enterprises in China, the top 500 manufacturing enterprises of private enterprises in China, and has been listed on Shandong Province's top 100 taxpayers for many consecutive years. It ranked 31st on the 2023 China Pharmaceutical Industry Top 100 List, and the brand value of Lunan Pharmaceutical reached 13.069 billion yuan in 2024.
Lunan Pharmaceutical Group has established multiple high-level R&D platforms, including the National Engineering Research Center for Chiral Pharmaceutical Technology, the National Engineering Laboratory for High-Efficiency Expression of Mammalian Cells, the National Key Laboratory for Integration and Innovation of Classical Prescriptions and Modern Chinese Medicine, and the nationally recognized enterprise technology center. It has established technical cooperation with more than 100 universities and research institutions at home and abroad. The innovation capability of its enterprise technology center ranks among the forefront of the national pharmaceutical industry, and it was listed on the 2017 China Enterprise Innovation Capability Top 100 List. It has won one second prize of the National Technological Invention Award and seven second prizes of the National Science and Technology Progress Award. In 2018, it was awarded the "Ho Leung Ho Lee Foundation Science and Technology Innovation Award," and in 2023, it received the National Innovation Prize. The enterprise has established a quality assurance system in line with international quality supervision concepts such as ICH, FDA, and EDQM. All dosage forms and varieties have passed the national new GMP certification. It has won the title of "Best Industrial Enterprise for Pharmaceutical R&D Pipeline in China" multiple times, with its overall quality management level ranking among the top in the same industry nationally. Several varieties have completed registration or certification in countries across Asia, Europe, America, and Africa. Clavulanate potassium, sevoflurane, and other API varieties have passed U.S. FDA certification. Isoflurane and other API varieties have obtained EU CEP certificates. Rosuvastatin calcium preparations and other products are exported to the United States, with multiple products sold to more than 80 countries and regions.
The enterprise's product quality, independent innovation capability, and management level are at the leading level in the industry. It was listed on the China Enterprise Patent Top 500 and ranked 117th on the 2023 National Private Enterprise R&D Investment Top 500 and 60th on the Private Enterprise Invention Patent Top 500. It won the sixth Shandong Province Governor Quality Award and the seventh China Industrial Grand Award.
The company always adheres to the business purpose of "benefiting society and creating a better life," upholds the enterprise spirit of "not fearing difficulties, challenging difficulties, and overcoming difficulties," and adheres to the development strategy of "reform as the driving force, market as the center, and science and technology as the guide." It has now developed into a national large-scale comprehensive pharmaceutical group and has been awarded the "National May 1 Labor Certificate," "National Model Staff Home," and "Advanced Unit in National Mass Sports," among other honors. It is committed to building an international century-old pharmaceutical national brand and making greater contributions to achieving the goals of "Healthy China and a Healthy World." Through exclusive sponsorship of CCTV's "Chinese Traditional Medicine Conference," CCTV Finance Channel's "Workplace Health Course," Shandong Radio and Television Station News Channel's "Healthy Shandong," and Phoenix TV's "Phoenix Big Health," it uses multiple channels and platforms to improve national health literacy, strengthen health education, and inject the concept of "preventing disease before it occurs" and "treating disease before it occurs" into health education. It is a CCTV national craftsmanship brand and signed a contract with CCTV in 2017 to become a "CCTV Health Public Welfare Partner."
Now in its prime and aiming for a global presence, Lunan Pharmaceutical Group is guided by "innovation leading and service driving," with the goal of "maintaining the advantage in chemical pharmaceuticals, vigorously developing traditional Chinese medicine, and strengthening biological pharmaceuticals." On the international path of revitalizing national medicine and creating a century-old brand, it is achieving new and greater strides!